Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Sotorasib + VIC-1911 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Sotorasib | Lumakras | AMG 510|AMG510|AMG-510|Lumykras | KRAS G12C inhibitor 34 | Lumakras (sotorasib) is small molecule inhibitor that selectively targets KRAS G12C and inhibits downstream signaling, which may lead to growth inhibition of tumors harboring KRAS G12C (PMID: 31666701). Lumakras (sotorasib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C who have received one or more prior therapy, and in combination with Vectibix (panitumumab) in patients with metastatic colorectal cancer harboring KRAS G12C who have received chemotherapy (FDA.gov). |
VIC-1911 | TAS-119|TAS-2104 | Aurka Inhibitors 27 | VIC-1911 (TAS-119) is a selective inhibitor of Aurora Kinase A, which potentially decreases tumor growth (Cancer Res 2023;83(7_Suppl):Abstract nr 429). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05374538 | Phase I | VIC-1911 Sotorasib + VIC-1911 | VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer | Terminated | USA | 0 |